ADC Therapeutics S.A.
ADCT
Rank in Stocks
#16387
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company,... ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Share Price
$1.67
Last synced: 2026-11-09
Market Cap
$213.21M
Change (1 day)
5.70%
Change (1 year)
-57.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ADC Therapeutics S.A. (ADCT)
Category
Healthcare
EPS for ADC Therapeutics S.A. (ADCT)
EPS as of June 2026 TTM: $-0.66
According to ADC Therapeutics S.A.'s latest financial reports, its current EPS (TTM) is $-0.66. At the end of 2025 the company had an EPS of $-1.12, an increase over its 2024 EPS of $-1.62.
EPS history for ADC Therapeutics S.A. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.66 | -41.07% |
| 2025 | $-1.12 | -30.86% |
| 2024 | $-1.62 | -44.90% |
| 2023 | $-2.94 | 47.74% |
| 2022 | $-1.99 | -33.67% |
| 2021 | $-3.00 | -20.42% |
| 2020 | $-3.77 | 116.67% |
| 2019 | $-1.74 | -24.02% |
| 2018 | $-2.29 | 49.67% |
| 2017 | $-1.53 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,472.73% |
US
|
|
| $-7.07 | 971.21% |
US
|
|
| $-5.29 | 701.52% |
AU
|
|
| $12.88 | -2,051.53% |
BE
|
|
| $21.56 | -3,366.67% |
NL
|
Questions about ADC Therapeutics S.A.'s earnings per share (EPS)
What is ADC Therapeutics S.A.'s earnings per share (EPS)?
ADC Therapeutics S.A.'s earnings per share (EPS) over the last twelve months is $-0.66, as of Jun 2026.
What was ADC Therapeutics S.A.'s earnings per share (EPS) in 2025?
In 2025, ADC Therapeutics S.A.'s earnings per share (EPS) was $-1.12, compared with $-1.62 in 2024.
How has ADC Therapeutics S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, ADC Therapeutics S.A.'s earnings per share (EPS) was highest in 2025 ($-1.12) and lowest in 2020 ($-3.77).
How does ADC Therapeutics S.A.'s earnings per share (EPS) compare with similar companies?
ADC Therapeutics S.A.'s earnings per share (EPS) ($-0.66) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.